AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 84.89 |
Market Cap | 4.10B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -6.58 |
PE Ratio (ttm) | -12.87 |
Forward PE | n/a |
Analyst | Buy |
Ask | 86 |
Volume | 562,933 |
Avg. Volume (20D) | 627,234 |
Open | 88.72 |
Previous Close | 89.27 |
Day's Range | 84.64 - 89.96 |
52-Week Range | 64.11 - 105.00 |
Beta | undefined |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial ...
Analyst Forecast
According to 14 analyst ratings, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is $121.5, which is an increase of 43.52% from the latest price.
Next Earnings Release
Analysts project revenue of $117.89M, reflecting a 64.81% YoY growth and earnings per share of -1.03, making a 41.10% increase YoY.
2 months ago · seekingalpha.com
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call TranscriptAxsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Ni...
2 months ago · seekingalpha.com
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then SellAxsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axso...